Search
You have executed a tag search on The Deal Pipeline. Below, you will find a comprehensive list of stories tagged "GlaxoSmithKline plc."
12 result(s) displayed (1 - 12 of 15)
Company looks to capture market share from Glaxo and Amarin with Epanova medicine. Continue reading
Posted on March 12, 2013 9:20 AM
Elan cedes control of the blockbuster multiple sclerosis drug, its sole revenue producer, in an attempt to pursue a new strategic direction through acquisitions. Continue reading
Posted on February 6, 2013 11:23 AM
Revenue at both businesses has been rising rapidly. Continue reading
Posted on November 26, 2012 10:44 AM
In a seldom-seen move, the Swiss pharma giant, the California venture capital firm and Inception Sciences will form an entity to create drugs to treat sensorineural hearing loss which Roche will then have an option to buy. Continue reading
Posted on October 15, 2012 10:41 AM
The pharmaceutical company's share price is buoyed by takeover speculation after its Alzheimer's compound fails a clinical trial Continue reading
Posted on August 8, 2012 9:08 AM
The British drug giant's raised offer values the biotech pioneer at $3.6 billion. Continue reading
Posted on July 16, 2012 1:30 PM
The Shanghai biotech services provider weighs a $8.50 to $9.50 per share bid for the 35% that the buyers don't already own Continue reading
Posted on July 9, 2012 9:39 AM
GlaxoSmithKline has tweaked the terms of its hostile $2.59 billion offer for Human Genome Sciences to address a poison pill its target put in place last week Continue reading
Posted on May 23, 2012 11:04 AM
The board rejects a hostile bid from the megapharma as opportunistic. Continue reading
Posted on May 17, 2012 4:44 PM
The drugs company says it won't participate in its target's formal review process Continue reading
Posted on May 9, 2012 9:23 AM
The biotech hires Goldman Sachs and Credit Suisse to explore its options after batting back its U.K. suitor. Continue reading
Posted on April 19, 2012 9:58 AM
GSK and J&J have teamed with Index Ventures to launch a fund to invest in life sciences companies Continue reading
Posted on March 21, 2012 3:22 PM
Movable Type search results powered by Fast Search
Ken deRegt will retire as head of fixed income at Morgan Stanley and be replaced by Michael Heaney and Robert Rooney. For other updates launch today's Movers & shakers slideshow.
Apax Partners offers $1.1 billion for Rue21, the same teenage fashion chain it took public in 2009. More video
